Welcome to our dedicated page for Inspiremd news (Ticker: NSPR), a resource for investors and traders seeking the latest updates and insights on Inspiremd stock.
InspireMD, Inc. (NSPR) is a medical device company whose news flow centers on its CGuard® Prime carotid stent system and proprietary MicroNet™ mesh technology for stroke prevention. Company press releases and SEC filings describe InspireMD as the developer of CGuard® Prime for the treatment of carotid artery stenosis, with a focus on making its products a standard approach in carotid stenting.
News about InspireMD often covers clinical milestones and peer-reviewed publications. For example, the company announced that results from its C-GUARDIANS pivotal trial of the CGuard® Prime carotid stent system were published in the Journal of the American College of Cardiology, with data showing low rates of disabling stroke or myocardial infarction through 30 days and low ipsilateral stroke rates through one year. InspireMD has also highlighted external clinical evidence such as the CREST-2 study in the New England Journal of Medicine, which it views as supportive of carotid artery stenting combined with medical therapy.
Investors following NSPR can also expect updates on regulatory and commercial developments. Recent filings report FDA PMA approval for the CGuard Prime Carotid Stent System in the United States and subsequent announcements of a U.S. commercial launch. Quarterly earnings releases describe the impact of CGuard Prime on revenue and provide commentary on procedure volumes and expansion of the company’s commercial team.
Additional news items include capital-raising transactions, such as private placements and warrant exercises, as well as changes in board composition and senior medical leadership. Together, these updates give readers insight into InspireMD’s clinical progress, regulatory status, commercialization efforts, and corporate governance. This page aggregates such NSPR news so readers can review the company’s key announcements in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
InspireMD (Nasdaq: NSPR) announced it will report Q1 2023 financial results on May 9, 2023, before market opening. A conference call will take place at 8:30 a.m. EDT the same day to discuss the results and provide a corporate update. The company focuses on developing the CGuard™ Embolic Prevention Stent System aimed at treating Carotid Artery Disease to prevent strokes. InspireMD seeks to position its technology as the industry standard for carotid stenting.
Forward-looking statements caution that actual results may differ from expectations due to a variety of risks including market acceptance, regulatory challenges, and competition. Investors can access detailed risk factors in InspireMD's SEC filings.
InspireMD reported a 25.7% decrease in total revenue for Q4 2022, totaling $1.03 million, with CGuard EPS sales down 20.6% to $1.03 million due to lapses in CE Mark certification. However, full-year revenue rose 15% to $5.17 million, driven by an 18.9% increase in CGuard sales. The net loss for Q4 2022 was $4.85 million, or $0.60 per share, up from a loss of $4.10 million in Q4 2021. Operating expenses increased by 21.5% to $5.13 million, influenced by FDA study-related costs. InspireMD has resumed CGuard shipments in CE Mark territories and is on track to complete U.S. trial enrollment by Q2 2023, with anticipated CE Mark re-certification in coming weeks.
InspireMD, Inc. has promoted Andrea Tommasoli to Chief Operating Officer, effective March 20, 2023. Tommasoli, who previously served as Senior Vice President of Global Sales & Marketing since 2020, has a strong background in the medical device industry, having held leadership positions at Integra LifeSciences and St. Jude Medical. His promotion comes at a pivotal time as the company enhances its operational capacity to support the commercial growth of its CGuard™ Embolic Prevention Stent System. CEO Marvin Slosman emphasized Tommasoli's significant contributions to expanding the CGuard EPS's market presence and his readiness to lead during this critical phase.
TEL AVIV, Israel, March 2, 2023 - InspireMD, Inc. (Nasdaq: NSPR) announced that it will release its fourth quarter and full-year 2022 financial results on March 30, 2023, before market open. The management will host a conference call at 8:30 a.m. EDT to discuss the results and provide a corporate update. This event is aimed at engaging the investment community and highlighting developments regarding its CGuard™ Embolic Prevention Stent System designed to treat Carotid Artery Disease and prevent strokes.